Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Uremia Retention Molecules and Clinical Outcomes.

Barreto FC, Barreto DV, Canziani MEF.

Contrib Nephrol. 2017;191:18-31. doi: 10.1159/000479253. Epub 2017 Sep 14.

PMID:
28910788
2.

A Novel Missense GLA Mutation (p.G35V) Detected in Hemodialysis Screening Leads to Severe Systemic Manifestations of Fabry Disease in Men and Women.

Veloso VSP, Ataides TL, Canziani MEF, Veloso MP, da Silva NA, Barreto DV, Pereira ERS, de Moura LAR, Barreto FC.

Nephron. 2018;138(2):147-156. doi: 10.1159/000479895. Epub 2017 Sep 12.

PMID:
28892806
3.

Comment on Indoxyl Sulfate-Review of Toxicity and Therapeutic Strategies. Toxins 2016, 8, 358.

Barreto FC, Barreto DV, Stinghen AEM, Massy ZA.

Toxins (Basel). 2017 Apr 17;9(4). pii: E142. doi: 10.3390/toxins9040142.

4.

The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.

Graciolli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, Sabbagh Y, Carvalho AB, Jorgetti V, Elias RM, Schiavi S, Moysés RMA.

Kidney Int. 2017 Jun;91(6):1436-1446. doi: 10.1016/j.kint.2016.12.029. Epub 2017 Mar 18.

PMID:
28318623
5.

The pitfall of treating low bone turnover: Effects on cortical porosity.

Araujo MJ, Karohl C, Elias RM, Barreto FC, Barreto DV, Canziani ME, Carvalho AB, Jorgetti V, Moyses RM.

Bone. 2016 Oct;91:75-80. doi: 10.1016/j.bone.2016.07.009. Epub 2016 Jul 15.

PMID:
27424935
6.

Impact of Pre-Dialysis Care on Clinical Outcomes in Peritoneal Dialysis Patients.

Spigolon DN, de Moraes TP, Figueiredo AE, Modesto AP, Barretti P, Bastos MG, Barreto DV, Pecoits-Filho R; BRAZPD Investigators.

Am J Nephrol. 2016;43(2):104-11. doi: 10.1159/000444401. Epub 2016 Mar 9.

7.

Overview of hemodialysis treatment funded by the Brazilian Unified Health System--An economic perspective.

Menezes FG, Barreto DV, Abreu RM, Roveda F, Pecoits Filho RF.

J Bras Nefrol. 2015 Jul-Sep;37(3):367-78. doi: 10.5935/0101-2800.20150057. English, Portuguese.

8.

Association between indoxyl sulfate and bone histomorphometry in pre-dialysis chronic kidney disease patients.

Barreto FC, Barreto DV, Canziani ME, Tomiyama C, Higa A, Mozar A, Glorieux G, Vanholder R, Massy Z, de Carvalho AB.

J Bras Nefrol. 2014 Jul-Sep;36(3):289-96. English, Portuguese.

9.

The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins.

Barreto FC, Stinghen AE, de Oliveira RB, Franco AT, Moreno AN, Barreto DV, Pecoits-Filho R, Drüeke TB, Massy ZA.

J Bras Nefrol. 2014 Apr-Jun;36(2):221-35. Review. English, Portuguese.

10.

Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease.

Neirynck N, Eloot S, Glorieux G, Barreto DV, Barreto FC, Liabeuf S, Lenglet A, Lemke HD, Massy ZA, Vanholder R.

PLoS One. 2012;7(8):e44201. doi: 10.1371/journal.pone.0044201. Epub 2012 Aug 31.

11.

Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloot S, Barreto FC, Massy Z, Vanholder R; European Uremic Toxin Work Group (EUTox).

Clin J Am Soc Nephrol. 2011 Oct;6(10):2374-83. doi: 10.2215/CJN.01720211. Epub 2011 Aug 4. Erratum in: Clin J Am Soc Nephrol. 2012 May;7(5):874.

12.

Inhibitors of vascular calcification as potential therapeutic targets.

Rezg R, Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA.

J Nephrol. 2011 Jul-Aug;24(4):416-27. doi: 10.5301/JN.2011.8420. Review.

PMID:
21688249
13.

Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins.

Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R.

Clin J Am Soc Nephrol. 2011 Jun;6(6):1266-73. doi: 10.2215/CJN.09981110. Epub 2011 May 26.

14.

[Plasma malondialdehyde may not predict mortality in patient with chronic kidney disease].

Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, Vanholder R, Choukroun G, Massy ZA; Groupe EUTox (European Uremic toxin).

Nephrol Ther. 2011 Jul;7(4):219-24. doi: 10.1016/j.nephro.2010.12.009. Epub 2011 Feb 11. French.

PMID:
21316322
15.

High circulating levels of large splice variants of tenascin-C is associated with mortality and cardiovascular disease in chronic kidney disease patients.

Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, Choukroun G, Massy Z.

Atherosclerosis. 2011 Mar;215(1):116-24. doi: 10.1016/j.atherosclerosis.2010.11.038. Epub 2010 Dec 5.

PMID:
21183183
16.

Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease.

Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z.

Nephron Clin Pract. 2011;117(4):c363-72. doi: 10.1159/000321520. Epub 2010 Nov 12.

PMID:
21071960
17.

Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.

Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM.

Nephron Clin Pract. 2011;117(1):c74-82. doi: 10.1159/000319650. Epub 2010 Aug 4.

PMID:
20689328
18.

Vascular calcification is not an independent predictor of mortality in pre-dialysis adult patients.

Barreto FC, Barreto DV, Liabeuf S, Massy ZA.

Nephrol Dial Transplant. 2010 Aug;25(8):2804-5; author reply 2805. doi: 10.1093/ndt/gfq289. Epub 2010 May 26. No abstract available.

PMID:
20507851
19.

Uraemic toxins for consideration by the cardiologist-Beyond traditional and non-traditional cardiovascular risk factors.

Massy ZA, Barreto DV, Barreto FC, Vanholder R.

Atherosclerosis. 2010 Aug;211(2):381-3. doi: 10.1016/j.atherosclerosis.2010.04.010. Epub 2010 May 14. No abstract available.

PMID:
20471651
20.

The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.

Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G, Kamel S, Massy ZA.

Nephrol Dial Transplant. 2010 Aug;25(8):2596-602. doi: 10.1093/ndt/gfq042. Epub 2010 Feb 26.

PMID:
20190248
21.

The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report.

Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA.

Clin J Am Soc Nephrol. 2010 Apr;5(4):568-75. doi: 10.2215/CJN.07081009. Epub 2010 Feb 4.

22.

Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.

Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox).

Kidney Int. 2010 Mar;77(6):550-6. doi: 10.1038/ki.2009.503. Epub 2009 Dec 16.

23.

Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.

Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox).

Nephrol Dial Transplant. 2010 Apr;25(4):1183-91. doi: 10.1093/ndt/gfp592. Epub 2009 Nov 13.

PMID:
19914995
24.

Effects of uremic toxins on vascular and bone remodeling.

Barreto FC, Barreto DV, Liabeuf S, Drüeke TB, Massy ZA.

Semin Dial. 2009 Jul-Aug;22(4):433-7. doi: 10.1111/j.1525-139X.2009.00595.x. Review.

PMID:
19708996
25.

Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.

Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox).

Clin J Am Soc Nephrol. 2009 Oct;4(10):1551-8. doi: 10.2215/CJN.03980609. Epub 2009 Aug 20.

26.

Vitamin D affects survival independently of vascular calcification in chronic kidney disease.

Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA.

Clin J Am Soc Nephrol. 2009 Jun;4(6):1128-35. doi: 10.2215/CJN.00260109. Epub 2009 May 14.

27.

Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.

Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME.

Nephron Clin Pract. 2008;110(4):c273-83. doi: 10.1159/000170783. Epub 2008 Nov 12.

PMID:
19001830
28.

Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients.

Rocha LA, Barreto DV, Barreto FC, Dias CB, Moysés R, Silva MR, Moura LA, Draibe SA, Jorgetti V, Carvalho AB, Canziani ME.

Clin J Am Soc Nephrol. 2009 Jan;4(1):105-9. doi: 10.2215/CJN.01630408. Epub 2008 Oct 8.

29.

Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study.

Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME.

Am J Kidney Dis. 2008 Dec;52(6):1139-50. doi: 10.1053/j.ajkd.2008.06.024. Epub 2008 Sep 27. Erratum in: Am J Kidney Dis. 2009 Jan;53(1):181.

PMID:
18824289
30.

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.

Barreto FC, Barreto DV, Moysés RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB.

Kidney Int. 2008 Mar;73(6):771-7. doi: 10.1038/sj.ki.5002769. Epub 2008 Jan 9.

31.

Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem.

Barreto FC, Barreto DV, Moyses RM, Neves CL, Jorgetti V, Draibe SA, Canziani ME, Carvalho AB.

Kidney Int. 2006 May;69(10):1852-7.

32.

Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors.

Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA, Moyses RM, Neves KR, Jorgetti V, Blair A, Guiberteau R, Fernandes Canziani ME.

Kidney Int. 2005 Apr;67(4):1576-82. Erratum in: Kidney Int. 2005 May;67(5):2085-7.

Supplemental Content

Loading ...
Support Center